Year: 2023

Global Bioinformatics Market Size to Reach USD 37.89 Billion in 2032 | Emergen Research

Written by Customer Service on November 6, 2023. Posted in Mergers And Acquisitions.

The global bioinformatics market is on a growth trajectory, driven by advancements in genomics, personalized medicine, and biotechnology. Vancouver, Nov. 06, 2023 (GLOBE NEWSWIRE) — The global bioinformatics market size was USD 10.80 Billion in 2022 and is expected to register a revenue CAGR of 13.4% during the forecast period. The market is benefiting from the growing adoption of bioinformatics in personalized medicine, biotechnology in agriculture, and ongoing advancements in genomics research. Bioinformatics, a category of computer programs used to analyze biological data, particularly in genomics and proteomics, is playing a vital role in various industries, such as pharmaceuticals and agriculture, by offering comprehensive solutions for data analysis and management. The increasing usage of bioinformatics software, including...

Global Artificial Intelligence in the Education Sector Market to Reach Value of USD 109.63 Billion by 2032 | Emergen Research

Written by Customer Service on November 6, 2023. Posted in Mergers And Acquisitions.

Growing demand for unique and interactive virtual learning courses and rising need for better-customized learning experience are factors driving global artificial intelligence in the education sector market growth. Vancouver, Nov. 06, 2023 (GLOBE NEWSWIRE) — The global artificial intelligence in the education sector market is forecast to reach a market size of USD 109.63 Billion by 2032 and register a significantly high CAGR, according to a current analysis by Emergen Research. Rising demand for unique and interactive virtual learning courses like game-based courses is a key factor driving growth of the global artificial intelligence in the education sector market, and this is further expected to increase rapidly over the forecast period. Rising need for better-customized learning experience in the education sector is expected...

Global Peristaltic Pumps Market Size to Reach USD 2,563.79 Million by 2032 | Emergen Research

Written by Customer Service on November 6, 2023. Posted in Mergers And Acquisitions.

Rising demand for peristaltic pumps from the water & wastewater treatment industry is one of the significant factors influencing the market growth Vancouver, Nov. 06, 2023 (GLOBE NEWSWIRE) — The global peristaltic pumps market is projected to be valued at USD 2,563.79 Million by 2032, according to a current analysis by Emergen Research. Peristaltic pumps are witnessing high demand, owing to increasing investments in drug development and discovery. Medical and pharmaceutical firms are exhibiting a growing inclination toward development of biopharmaceutical products. As several large-molecule drugs are administered through injection, deployment of fill-finish operations and aseptic liquid processing becomes a necessity. Peristaltic pumps contain a biopharmaceutical fluid inside a pharmaceutical-grade tubing, the only part of...

Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

Written by Customer Service on November 6, 2023. Posted in Earnings Releases And Operating Results.

Updated data from azenosertib monotherapy study with longer follow up shows 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients Azenosertib programs on track for first NDA submission in a gynecologic malignancy in 2026 Sharing key clinical milestones through 2026 for azenosertib and ZN-d5 $517 million cash balance as of September 30, 2023, with projected cash runway into 2026 Chief Translational Officer, Mark Lackner, Ph.D., to succeed Co-Founder, Kevin Bunker, Ph.D., as Chief Scientific Officer NEW YORK and SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced...

ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

Written by Customer Service on November 6, 2023. Posted in Public Companies.

LAUSANNE, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) — ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 14th at 10:00 a.m. GMT. A live webcast of the fireside chat will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics’...

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

Written by Customer Service on November 6, 2023. Posted in Public Companies.

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has further strengthened its leading intellectual property (IP) estate with the issuance of a new patent in the United States and that it has successfully defended against an opposition to its IP in Japan. “The new patent that the USPTO granted to ProQR further expands the protection of RNA editing using oligonucleotides to recruit endogenous ADAR. Our leading intellectual property portfolio protects our Axiomer® ADAR-mediated RNA editing platform technology and more fundamentally the use of an oligonucleotide to recruit endogenous deaminating enzymes in the cell,” said René Beukema, Chief Corporate Development...

ECARX Delivers ADAS Platform to Global Car Manufacturers

Written by Customer Service on November 6, 2023. Posted in Public Companies.

SHANGHAI, China, Nov. 06, 2023 (GLOBE NEWSWIRE) — ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX”), a global provider of mobility technology, has today announced a new series of Advanced Driver Assistance System (ADAS) enabled products, starting with the ECARX Skyland Pro. It will support drivers as the autonomy of their vehicles increases. Delivery of this ECARX ADAS platform has already taken place, with the beginning of its mass production marking a significant milestone for the company. Owing to its dual system-on-chip (SoC) architecture, ECARX Skyland Pro delivers exceptional performance, and is supported by a sophisticated safety system. Empowered by two Black Sesame Huashan-2 A1000 automotive-grade SoCs that deliver a comprehensive computing power of 116 tera operations per second (TOPS) at 8-bit integer (INT8), the...

Paramount’s Grassy Mountain Receives Notice to Proceed From Oregon State Regulators

Written by Customer Service on November 6, 2023. Posted in Public Companies.

WINNEMUCCA, Nev., Nov. 06, 2023 (GLOBE NEWSWIRE) — Post the receipt of the positive completeness determination announced on October 5th, Paramount Gold Nevada Corp. (NYSE American: PZG) (“Paramount” or the “Company”) is pleased to announce that the Oregon Department of Geology and Mineral Industries (“DOGAMI”) has issued the Notice to Proceed (the “Notice” or “NTP”) required to move Grassy Mountain into the next phase of permitting. Based on state regulations, it is expected that the DOGAMI will issue the final consolidated permit package within one year. Paramount President, COO and Director, Glen Van Treek commented: “The Notice is a critical milestone in securing the permits to build and operate Grassy. Paramount will continue to work collaboratively with the agencies as they move through the next important steps to achieving...

TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting

Written by Customer Service on November 6, 2023. Posted in Public Companies.

Solid tumor program uses separate screening protocol designed to identify patients in advance of treatment protocol; on track to enroll first patient in study this year Company adds TSC-201-B0702 to ImmunoBank, targeting novel melanoma-associated antigen C2 (MAGE-C2) WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the presentation of six posters at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. “Solid tumors are notoriously heterogenous, which may contribute to low response rates and limited duration of response following treatment with single-targeting TCR-T cell therapy. TScan’s...

Tecnoglass Reports Strong Third Quarter 2023 Results and Projects Double-Digit Top Line Growth in 2024

Written by Customer Service on November 6, 2023. Posted in Public Companies.

– Revenue Growth of 4.4% to $210.7 Million, Entirely Organic, Including a Record $87.8 Million in the Single-Family Residential End Market – – Quarterly Cash Flow from Operations at an All-Time High of $51.3 Million – – Net Income of $46.1 Million, or $0.97 Per Diluted Share – – Adjusted Net Income1 of $46.6 Million, or $0.98 Per Diluted Share – – Gross Margin of 43.0% Included a Non-Cash 660 Basis Point Impact from Unfavorable FX Compared to Prior Year Quarter – – Adjusted EBITDA1 of $71.3 Million, with 340 Basis Points of SG&A Improvement Blunting the Gross Margin Impact Compared to Prior Year Quarter – – Continued Strong Backlog Growth, Expanding 20% Year-Over-Year to a Record $836 Million – – Executed 40% of Repurchase Program Totaling $20...

Year: 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals